Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.78 |
| ▸ | ACHE | P22303 | 3/20 | 0.74 |
| ▸ | NPC1 | O15118 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 4/20 | 0.69 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | MGAM | O43451 | 1/20 | 0.51 |
| ▸ | SI | P14410 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Marmesin Acetate SCHEMBL12062110 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4EHSD17B10L3MBTL1 | |
| (-)-Prantschimgin SCHEMBL13337338 | 0.88 | ALDH1A1 (0.78) | ALDH1A1HPGDKDM4EHSD17B10L3MBTL1 | |
| Felamidin SCHEMBL30467160 | 0.86 | ALDH1A1 (0.75) | ALDH1A1HPGDKDM4EHSD17B10L3MBTL1 | |
| Felamidin SCHEMBL12062114 | 0.86 | ALDH1A1 (0.75) | ALDH1A1HPGDKDM4EHSD17B10L3MBTL1 | |
| Marmesin SCHEMBL12062107 | 0.85 | ACHE (1.00) | ALDH1A1HPGDKDM4EHSD17B10L3MBTL1 | |
| Marmesin SCHEMBL29471037 | 0.85 | ACHE (1.00) | ALDH1A1HPGDKDM4EHSD17B10L3MBTL1 | |
| Marmesin SCHEMBL30977125 | 0.85 | ACHE (1.00) | ALDH1A1HPGDKDM4EHSD17B10L3MBTL1 | |
| Marmesin SCHEMBL546574 | 0.85 | ACHE (1.00) | ALDH1A1HPGDKDM4EHSD17B10L3MBTL1 | |
| SCHEMBL30777266 | 0.83 | ALDH1A1 (0.71) | ALDH1A1HPGDKDM4EHSD17B10L3MBTL1 | |
| Marmesin SCHEMBL503874 | 0.79 | ACHE (0.86) | ALDH1A1HPGDKDM4EHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10161929-B2 | Theranostics platform and methods of use | Sanford Burnham Prebys Medical Discovery (US) | 2018-12-25 | — | — | US | disclosed |
| US-8772252-B2 | Coumarin compounds as melanogenesis modifiers and uses thereof | NEW YORK UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8563754-B2 | Compounds, compositions and methods for preventing skin darkening | NEW YORK UNIVERSITY (US) | 2013-10-22 | — | — | US | disclosed |
| WO-2013123403-A1 | THERANOSTICS PLATFORM AND METHODS OF USE | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | NEW YORK UNIVERSITY | 2012-08-30 | — | — | US | disclosed |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | NEW YORK UNIVERSITY | 2011-08-04 | — | — | US | disclosed |
| US-20090269772-A1 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST | THERASIS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-2008156654-A2 | CYTOSKELETON MODULATORS FOR TREATING METABOLIC DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220545-A1 | COUMARIN COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF | TYR, MC1R, MITF | ALDH1A1 246/4885HPGD 2055/4885KDM4E 79/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | ALDH1A1 860/4885HPGD 503/4885KDM4E 3739/4885 |
| US-20110190229-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PREVENTING SKIN DARKENING | TYR, MC1R, MITF | ALDH1A1 397/4885HPGD 574/4885KDM4E 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.